他分析，中美格局决定了行情节奏，行情可能将被中美签署贸易协议和美国中期选举分为三段：第一阶 段从当前到中美贸易协议落地前，市场上涨斜率预计放缓；第二阶段是协议落地到美国中期选举结束， A股有望在稳定的外部环境下迎来持续上涨；第三阶段是美国中期选举结束后，外部扰动的不确定性可 能会急剧提高，投资者需要把视野重心转回国内。 裘翔认为，从主题投资机会和板块配置来看，四大线索值得重视：一是制造业争夺全球定价权，资源、 传统制造产业升级，把份额优势转化为定价权和利润率的持续抬升，可关注的重点大类行业包括有色、 化工和新能源；二是中企出海与全球化，大幅打开了市值天花板和利润增长空间，可重点关注大类行业 包括机械、创新药、电力设备、军工；三是科技行情延续，AI(人工智能)进一步拓展商用版图，延续科 技趋势并放大中企相对竞争优势，相关重点大类行业包括：半导体、算力、端侧硬件、AI应用；四是 关注内需的超预期修复机会，内需敞口品种景气度虽然一般，但也潜藏着较大的修复空间和估值弹性。 (刘艺文) 中信证券首席A股策略师裘翔认为，2026年A股公司盈利增速将呈现前低后高态势。 ...

Group 1: Macro Strategy - The current A-share market resembles the early stages of the 2020-2021 bull market, indicating a slow bull phase driven by strategic funds, similar to the role of foreign capital in early 2020 [1][11] - The market is expected to follow a structural "innovation bull" trend in 2026, as new funds and improved performance from domestic institutions emerge [1][11] - The macroeconomic environment in 2025 shows a mild recovery driven by policy support, with significant similarities to the early 2020 recovery phase [1][11] Group 2: Fixed Income Market - The bond market remains in a box range, with the central bank maintaining liquidity through reverse repos and net purchases of government bonds [2][12] - The introduction of new redemption fee regulations is anticipated to cause volatility in the bond market, but a cautious optimism is advised as the impact will be spread over time [2][12] - The 10-year government bond yield is expected to continue a narrow range of fluctuations, with potential entry points if rates rise sharply due to new regulations [2][12] Group 3: Industry Insights - Aojie Technology is a rare domestic wireless communication baseband chip manufacturer, focusing on four main product categories, including baseband chips and ASICs [6][22] - The company is in a technology accumulation phase, with expectations of turning profitable as technology matures and product lines expand [6][22] - The market for cellular IoT is projected to enter a rapid expansion phase over the next six years, driven by advancements in 5G technology [6][22] Group 4: Company Performance - Baiji Shenzhou's core product, Zebutinib, is experiencing significant growth, with revenue projections for 2025-2027 revised upwards, indicating strong profit potential [7][9] - The company is expected to achieve rapid profit release in the coming years due to scale effects and improved cost management [7][9] - Baiji Shenzhou is positioned as a leading domestic innovative drug company, with a strong global commercialization capability [7][9]